Role of erlotinib in the treatment of non-small cell lung cancer

Clinical outcomes in wild-type epidermal growth factor receptor patients

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150mg is approved for the treatment of unselected chemorefractory advanced non-small cell lung cancer patients as well as maintenance therapy after first-line chemotherapy. The European Medicines Agency has recently also approved erlotinib as the first-line therapy in patients with EGFR mutations. Although recent studies have identified higher response rates and improved survival with erlotinib in a subset of patients with EGFR mutations, the survival benefit from single agent erlotinib in chemorefractory patients and in the maintenance setting is well observed in EGFR wild-type patients. The role of single agent erlotinib in the first-line setting in special subsets of EGFR wild-type patients (elderly, poor performance status, non-smokers) needs to be further determined. The combination of erlotinib with other targeted therapies has shown promising results and warrants further studies in EGFR wild-type patients. Adis

Original languageEnglish (US)
Pages (from-to)11-19
Number of pages9
JournalDrugs
Volume72
Issue numberSUPPL. 1
DOIs
StatePublished - 2012

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Therapeutics
Mutation
Erlotinib Hydrochloride
Protein-Tyrosine Kinases
Survival Rate
Maintenance
Drug Therapy
Survival

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{037821d9dcac4ac38829482625c2045f,
title = "Role of erlotinib in the treatment of non-small cell lung cancer: Clinical outcomes in wild-type epidermal growth factor receptor patients",
abstract = "Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150mg is approved for the treatment of unselected chemorefractory advanced non-small cell lung cancer patients as well as maintenance therapy after first-line chemotherapy. The European Medicines Agency has recently also approved erlotinib as the first-line therapy in patients with EGFR mutations. Although recent studies have identified higher response rates and improved survival with erlotinib in a subset of patients with EGFR mutations, the survival benefit from single agent erlotinib in chemorefractory patients and in the maintenance setting is well observed in EGFR wild-type patients. The role of single agent erlotinib in the first-line setting in special subsets of EGFR wild-type patients (elderly, poor performance status, non-smokers) needs to be further determined. The combination of erlotinib with other targeted therapies has shown promising results and warrants further studies in EGFR wild-type patients. Adis",
author = "Bilal Piperdi and Roman Perez-Soler",
year = "2012",
doi = "10.2165/1163018-S0-000000000-00000",
language = "English (US)",
volume = "72",
pages = "11--19",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Role of erlotinib in the treatment of non-small cell lung cancer

T2 - Clinical outcomes in wild-type epidermal growth factor receptor patients

AU - Piperdi, Bilal

AU - Perez-Soler, Roman

PY - 2012

Y1 - 2012

N2 - Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150mg is approved for the treatment of unselected chemorefractory advanced non-small cell lung cancer patients as well as maintenance therapy after first-line chemotherapy. The European Medicines Agency has recently also approved erlotinib as the first-line therapy in patients with EGFR mutations. Although recent studies have identified higher response rates and improved survival with erlotinib in a subset of patients with EGFR mutations, the survival benefit from single agent erlotinib in chemorefractory patients and in the maintenance setting is well observed in EGFR wild-type patients. The role of single agent erlotinib in the first-line setting in special subsets of EGFR wild-type patients (elderly, poor performance status, non-smokers) needs to be further determined. The combination of erlotinib with other targeted therapies has shown promising results and warrants further studies in EGFR wild-type patients. Adis

AB - Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150mg is approved for the treatment of unselected chemorefractory advanced non-small cell lung cancer patients as well as maintenance therapy after first-line chemotherapy. The European Medicines Agency has recently also approved erlotinib as the first-line therapy in patients with EGFR mutations. Although recent studies have identified higher response rates and improved survival with erlotinib in a subset of patients with EGFR mutations, the survival benefit from single agent erlotinib in chemorefractory patients and in the maintenance setting is well observed in EGFR wild-type patients. The role of single agent erlotinib in the first-line setting in special subsets of EGFR wild-type patients (elderly, poor performance status, non-smokers) needs to be further determined. The combination of erlotinib with other targeted therapies has shown promising results and warrants further studies in EGFR wild-type patients. Adis

UR - http://www.scopus.com/inward/record.url?scp=84862563024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862563024&partnerID=8YFLogxK

U2 - 10.2165/1163018-S0-000000000-00000

DO - 10.2165/1163018-S0-000000000-00000

M3 - Article

VL - 72

SP - 11

EP - 19

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - SUPPL. 1

ER -